Campo DC | Valor | Idioma |
dc.contributor.author | Machado, Paulo Roberto Lima | - |
dc.contributor.author | Ampuero, Julia | - |
dc.contributor.author | Guimarães, Luiz H. | - |
dc.contributor.author | Villasboas, Leonardo | - |
dc.contributor.author | Rocha, Ana T. | - |
dc.contributor.author | Schriefer, Nicolaus Albert Borges | - |
dc.contributor.author | Sousa, Rosana Santos | - |
dc.contributor.author | Talhari, Anette Chrusciak | - |
dc.contributor.author | Penna, Gerson de Oliveira | - |
dc.contributor.author | Carvalho Filho, Edgar Marcelino de | - |
dc.creator | Machado, Paulo Roberto Lima | - |
dc.creator | Ampuero, Julia | - |
dc.creator | Guimarães, Luiz H. | - |
dc.creator | Villasboas, Leonardo | - |
dc.creator | Rocha, Ana T. | - |
dc.creator | Schriefer, Nicolaus Albert Borges | - |
dc.creator | Sousa, Rosana Santos | - |
dc.creator | Talhari, Anette Chrusciak | - |
dc.creator | Penna, Gerson de Oliveira | - |
dc.creator | Carvalho Filho, Edgar Marcelino de | - |
dc.date.accessioned | 2013-07-26T17:45:15Z | - |
dc.date.available | 2013-07-26T17:45:15Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.issn | 1935-2727 | - |
dc.identifier.uri | http://www.repositorio.ufba.br/ri/handle/ri/12312 | - |
dc.description | p. 1-6 | pt_BR |
dc.description.abstract | Background: Cutaneous leishmaniasis (CL) is treated with parenteral drugs for decades with decreasing rate cures. Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance.
Methodology/Principal Findings: This study is a randomized, open-label, controlled clinical trial aimed to evaluate the efficacy and safety of miltefosine versus pentavalent antimony (Sbv) in the treatment of patients with CL caused by Leishmania braziliensis in Bahia, Brazil. A total of 90 patients were enrolled in the trial; 60 were assigned to receive miltefosine and 30 to receive Sbv. Six months after treatment, in the intention-to-treat analyses, the definitive cure rate was 53.3% in the Sbv group and 75% in the miltefosine group (difference of 21.7%, 95% CI 0.08% to 42.7%, p = 0.04). Miltefosine was more effective than Sbv in the age group of 13–65 years-old compared to 2–12 years-old group (78.9% versus 45% p = 0.02; 68.2% versus 70% p = 1.0, respectively). The incidence of adverse events was similar in the Sbv and miltefosine groups (76.7% vs. 78.3%). Vomiting (41.7%), nausea (40%), and abdominal pain (23.3%) were significantly more frequent in the miltefosine group while arthralgias (20.7%), mialgias (20.7%) and fever (23.3%) were significantly more frequent in the Sbv group.
Conclusions: This study demonstrates that miltefosine therapy is more effective than standard Sbv and safe for the treatment of CL caused by Leishmania braziliensis in Bahia, Brazil. | pt_BR |
dc.language.iso | en_US | pt_BR |
dc.source | http://www.plosntds.org/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pntd.0000912&representation=PDF | pt_BR |
dc.title | Miltefosine in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis in Brazil: a randomized and controlled trial | pt_BR |
dc.title.alternative | PLoS Neglected Tropical Diseases | pt_BR |
dc.type | Artigo de Periódico | - |
dc.type | Artigo de Periódico | pt_BR |
dc.identifier.number | v. 4, n. 12 | pt_BR |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina)
|